Related Experiment Video

Updated: Aug 26, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.3K

How useful is chemotherapy for atypical and anaplastic meningiomas?

Jan Drappatz1

  • 1Departments of Neurology and Medicine, Division of Hematology and Oncology, Center for Neuro-Oncology, Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Expert Opinion on Pharmacotherapy
|October 3, 2022
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Anaplastic meningiomaatypical meningiomachemotherapygenomic profilingmalignant meningiomatargeted therapy

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Related Experiment Videos

Last Updated: Aug 26, 2025

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.3K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

418
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
418
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

249
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
249

Articles linked to this work by shared authors, journal, and citation graph.

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Nature medicine·2026

Clinical outcomes after transition from weight-based to fixed-dose glucarpidase for high-dose methotrexate toxicity at a large academic medical center.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Clinical characteristics and outcomes of adult IDH-mutant brainstem gliomas: Institutional case series and systematic review.

Neuro-oncology advances·2026

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

The Effect of Environmental Vulnerability on Family Caregiver Health.

Oncology nursing forum·2026

Evaluating bezuclastinib for the treatment of advanced gastrointestinal stromal tumours.

Expert opinion on pharmacotherapy·2026

Evaluating the combination of bictegravir and lenacapavir as a single tablet option for HIV.

Expert opinion on pharmacotherapy·2026

Pharmacotherapy for chronic migraine prevention: a narrative review.

Expert opinion on pharmacotherapy·2026

Contemporary pharmacological management of anemia associated with chronic kidney disease.

Expert opinion on pharmacotherapy·2026

Revisiting the role of danazol in the contemporary management of endometriosis-related pain: a systematic review.

Expert opinion on pharmacotherapy·2026

Natural estrogens: the new reference in contraception. An Italian expert opinion paper.

Expert opinion on pharmacotherapy·2026

UBA1 enhances phagocytosis by suppressing CD47 expression in small cell lung cancer.

Frontiers in oncology·2026

From the invasive front to organotropic pre-metastatic niches: spatial immune regulatory networks governing cholangiocarcinoma dissemination and metastasis-intercepting immunotherapy.

Frontiers in immunology·2026

[On a model of cisplatin-induced ototoxicity in Wistar rats].

Vestnik otorinolaringologii·2026

Comparative efficacy and safety of traditional Chinese medicine injections combined with chemotherapy for advanced non-small cell lung cancer: a Bayesian network meta-analysis.

Frontiers in immunology·2026

Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example.

Clinical and translational science·2026

Targeting cellular senescence mitigates chemotherapy-induced bone loss in young and aged mice.

GeroScience·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us